<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144949</url>
  </required_header>
  <id_info>
    <org_study_id>SIL1001</org_study_id>
    <nct_id>NCT01144949</nct_id>
  </id_info>
  <brief_title>Study of Silodosin to Facilitate Passage of Urinary Stones</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of Silodosin to Facilitate Urinary Stone Passage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Watson Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Watson Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if patients treated with silodosin will have a higher
      spontaneous passage rate of their ureteral stone than those treated with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.</measure>
    <time_frame>4 weeks</time_frame>
    <description>The primary efficacy variable is the occurrence of spontaneous distal stone passage within 4 weeks, as determined by radiography.
For this outcome measure, analysis includes only those stones located in the distal ureter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spontaneous Stone Passage (All Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.</measure>
    <time_frame>4 weeks</time_frame>
    <description>The primary efficacy variable is the occurrence of spontaneous stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes all ureteral stones, regardless of location in the ureter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Spontaneous Stone Passage (Distal Stones)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Time to stone passage for distally-located stones is assessed by entries in subject diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outpatient Narcotic Analgesic Use for Pain Relief</measure>
    <time_frame>4 weeks</time_frame>
    <description>Narcotic analgesic use was assessed through a subject diary. Analysis was performed on the number of days with analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Score on the Brief Pain Inventory (Distal Stones)</measure>
    <time_frame>4 weeks</time_frame>
    <description>At each study visit, subjects were given a Brief Pain Inventory (BPI) Questionnaire to complete. The BPI collects subject-reported pain severity scores and assesses impact of pain upon the subject's daily life, on a 10-point scale (with 10 being the greatest severity/impact). Analysis was change from baseline to week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Spontaneous Stone Passage (All Stones)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Time to stone passage for all ureteral stones (regardless of location) is assessed by entries in subject diaries.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Ureteral Calculi</condition>
  <condition>Kidney Stones</condition>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>silodsosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>silodosin</intervention_name>
    <description>one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks</description>
    <arm_group_label>silodsosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one placebo capsule orally, once daily, with food for up to 4 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age or older

          -  Male or a non-pregnant, non-lactating female using adequate means of birth control, if
             not menopausal

          -  Have radiopaque unilateral ureteral calculus ≥4mm and ≤10mm in any location of the
             ureter

        Exclusion Criteria:

          -  Multiple ureteral calculi, or a solitary kidney, or refractory renal colic, or a
             non-opaque calculus, or active urinary tract infection, or severe hydronephrosis

          -  History of previous ureteral surgery or ureteral stricture on affected side

          -  History of any of the following conditions: myasthenia gravis, myopathy, spina bifida,
             spinal cord injury, autonomic nervous system disorder, fibromyalgia, breast cancer

          -  Moderate to severe renal impairment or severe liver insufficiency

          -  History of significant postural hypotension

          -  Is receiving medication(s) which preclude safe participation in the study or that may
             produce a confounding effect on the variables under study

          -  History of allergy to alpha-blockers or oxycodone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Olsen, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Watson Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigative Site</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigative Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigative Site</name>
      <address>
        <city>North Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Mt Laurel</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Sewell</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <results_first_submitted>February 7, 2014</results_first_submitted>
  <results_first_submitted_qc>July 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2014</results_first_posted>
  <last_update_submitted>July 21, 2014</last_update_submitted>
  <last_update_submitted_qc>July 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ureteral calculi</keyword>
  <keyword>renal colic</keyword>
  <keyword>ureteral stones</keyword>
  <keyword>kidney stones</keyword>
  <keyword>medical expulsive therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silodosin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Silodsosin</title>
          <description>silodosin: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo: one placebo capsule orally, once daily, with food for up to 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Silodsosin</title>
          <description>silodosin: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo: one placebo capsule orally, once daily, with food for up to 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="239"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.4" spread="12.5"/>
                    <measurement group_id="B2" value="46.7" spread="15.2"/>
                    <measurement group_id="B3" value="47.0" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.</title>
        <description>The primary efficacy variable is the occurrence of spontaneous distal stone passage within 4 weeks, as determined by radiography.
For this outcome measure, analysis includes only those stones located in the distal ureter.</description>
        <time_frame>4 weeks</time_frame>
        <population>Those subjects in the ITT population (defined as randomized and received at least one dose of study drug) with stones located in the distal ureter (determined by radiography) were included in this analysis. The number of ITT subjects with distal stones was 52/115 in the 8 mg silodosin treatment arm and 59/117 in the placebo treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Silodsosin</title>
            <description>silodosin: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: one placebo capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.</title>
          <description>The primary efficacy variable is the occurrence of spontaneous distal stone passage within 4 weeks, as determined by radiography.
For this outcome measure, analysis includes only those stones located in the distal ureter.</description>
          <population>Those subjects in the ITT population (defined as randomized and received at least one dose of study drug) with stones located in the distal ureter (determined by radiography) were included in this analysis. The number of ITT subjects with distal stones was 52/115 in the 8 mg silodosin treatment arm and 59/117 in the placebo treatment arm.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Spontaneous Stone Passage (Distal Stones)</title>
        <description>Time to stone passage for distally-located stones is assessed by entries in subject diaries.</description>
        <time_frame>4 weeks</time_frame>
        <population>Those subjects in the ITT population (defined as randomized and received at least one dose of study drug) with stones located in the distal ureter (determined by radiography) were included in this analysis. The number of ITT subjects with distal stones was 52/115 in the 8 mg silodosin treatment arm and 59/117 in the placebo treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Silodsosin</title>
            <description>silodosin: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: one placebo capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Spontaneous Stone Passage (Distal Stones)</title>
          <description>Time to stone passage for distally-located stones is assessed by entries in subject diaries.</description>
          <population>Those subjects in the ITT population (defined as randomized and received at least one dose of study drug) with stones located in the distal ureter (determined by radiography) were included in this analysis. The number of ITT subjects with distal stones was 52/115 in the 8 mg silodosin treatment arm and 59/117 in the placebo treatment arm.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="1.61" lower_limit="12" upper_limit="29"/>
                    <measurement group_id="O2" value="22.0" spread="1.47" lower_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outpatient Narcotic Analgesic Use for Pain Relief</title>
        <description>Narcotic analgesic use was assessed through a subject diary. Analysis was performed on the number of days with analgesic use.</description>
        <time_frame>4 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Silodsosin</title>
            <description>silodosin: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: one placebo capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Outpatient Narcotic Analgesic Use for Pain Relief</title>
          <description>Narcotic analgesic use was assessed through a subject diary. Analysis was performed on the number of days with analgesic use.</description>
          <population>ITT population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="8.0"/>
                    <measurement group_id="O2" value="5.5" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Score on the Brief Pain Inventory (Distal Stones)</title>
        <description>At each study visit, subjects were given a Brief Pain Inventory (BPI) Questionnaire to complete. The BPI collects subject-reported pain severity scores and assesses impact of pain upon the subject’s daily life, on a 10-point scale (with 10 being the greatest severity/impact). Analysis was change from baseline to week 4.</description>
        <time_frame>4 weeks</time_frame>
        <population>Those subjects in the ITT population (defined as randomized and received at least one dose of study drug) with stones located in the distal ureter (determined by radiography) were included in this analysis. The number of ITT subjects with distal stones was 52/115 in the 8 mg silodosin treatment arm and 59/117 in the placebo treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Silodsosin</title>
            <description>silodosin: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: one placebo capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Score on the Brief Pain Inventory (Distal Stones)</title>
          <description>At each study visit, subjects were given a Brief Pain Inventory (BPI) Questionnaire to complete. The BPI collects subject-reported pain severity scores and assesses impact of pain upon the subject’s daily life, on a 10-point scale (with 10 being the greatest severity/impact). Analysis was change from baseline to week 4.</description>
          <population>Those subjects in the ITT population (defined as randomized and received at least one dose of study drug) with stones located in the distal ureter (determined by radiography) were included in this analysis. The number of ITT subjects with distal stones was 52/115 in the 8 mg silodosin treatment arm and 59/117 in the placebo treatment arm.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="2.5"/>
                    <measurement group_id="O2" value="-1.9" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Spontaneous Stone Passage (All Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.</title>
        <description>The primary efficacy variable is the occurrence of spontaneous stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes all ureteral stones, regardless of location in the ureter.</description>
        <time_frame>4 weeks</time_frame>
        <population>This endpoint analyzed all subjects in the ITT population, defined as randomized and received at least one dose of study drug (115 in the 8 mg silodosin arm, 117 in the placebo arm)</population>
        <group_list>
          <group group_id="O1">
            <title>Silodsosin</title>
            <description>silodosin: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: one placebo capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Spontaneous Stone Passage (All Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.</title>
          <description>The primary efficacy variable is the occurrence of spontaneous stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes all ureteral stones, regardless of location in the ureter.</description>
          <population>This endpoint analyzed all subjects in the ITT population, defined as randomized and received at least one dose of study drug (115 in the 8 mg silodosin arm, 117 in the placebo arm)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Spontaneous Stone Passage (All Stones)</title>
        <description>Time to stone passage for all ureteral stones (regardless of location) is assessed by entries in subject diaries.</description>
        <time_frame>4 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Silodsosin</title>
            <description>silodosin: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: one placebo capsule orally, once daily, with food for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Spontaneous Stone Passage (All Stones)</title>
          <description>Time to stone passage for all ureteral stones (regardless of location) is assessed by entries in subject diaries.</description>
          <population>ITT population</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="1.02" lower_limit="26" upper_limit="31"/>
                    <measurement group_id="O2" value="22.9" spread="1.00" lower_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Silodsosin</title>
          <description>silodosin: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo: one placebo capsule orally, once daily, with food for up to 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Retrograde ejaculation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gary Hoel, RPh PhD, VP Global Brands Clinical Research</name_or_title>
      <organization>Watson Laboratories, Inc.</organization>
      <phone>801 588-6641</phone>
      <email>gary.hoel@watson.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

